RECRUITINGOBSERVATIONAL
A National Registry on Chinese Patients With Cystic Fibrosis
A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Cystic Fibrosis (CF-CHINA)
About This Trial
Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.
Who May Be Eligible (Plain English)
Who May Qualify:
Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed willing to sign a consent form.
Who Should NOT Join This Trial:
Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent.
Exclusion Criteria:
Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China